Introduction
The availability and integrated use of advanced genome analysis platforms in recent years by consortia such as the Human Genome Project, Functional Annotation of the Mammalian genome project (FANTOM), and the Encyclopedia of DNA elements (ENCODE) project, have revealed that only a very small proportion of the actively transcribed human genome corresponds to protein-coding genes (Dingemans et al., 2014; Fatemi, Velmeshev, & Faghihi, 2014; Z. Zhang et al., 2014) . The recognition and identification of transcribed RNAs such as the microRNAs that do not encode for proteins but yet have specific biological functions have prompted a re-evaluation of the central dogma and emphasize a versatile role of RNA beyond that of a transitional role in translation of DNA to protein. The large numbers of pervasive non-coding RNA transcripts allows us to presume that many functionally active and biologically relevant non-coding RNA (ncRNA) remain to be identified. Considering their ubiquitous presence and diversity, these non-coding RNA could be major contributors to normal cellular physiological processes.
Classification of RNA genes
NcRNAs can be arbitrarily classified into two groups based on the length of their transcripts. Small RNAs, with less than 200 nucleotides, include several distinct types of RNAs such as microRNAs, small nucleolar RNAs, PIWI-interacting RNAs, and endogenous small interfering RNAs. Long RNAs, greater than 200 nucleotides, include long intergenic non-coding RNAs (lincRNAs), natural antisense transcripts (NATs), transcribed ultra-conserved regions (T-UCRs), long enhancer ncRNAs, non-coding repeat sequences, and pseudogenes. In contrast to some types of small ncRNAs such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), the mechanism and functions of long ncRNAs (lncRNAs) are very poorly understood (Dingemans et al., 2014; Kimura et al., 2015; Y. Yang, H. Li et al., 2013) .
The lncRNAs are a highly abundant and heterogeneous group, in part reflecting their enormous diversity and structural complexity. Pointers to a functional biological role include the recognition of tissue-specific expression patterns, emerging literature showing functional relevance in complex physiological and pathological processes, and evidence of their involvement in several human diseases. In contrast to the protein coding genes, the number of lncRNAs has increased tremendously along the evolutionary process and reflects the complexity of the organism. (Necsulea et al., 2014) . Despite this, an effective and useful method to categorize this large and heterogeneous group is lacking. A descriptive classification is based on genomic proximity to protein-coding genes. Depending on genomic location, they can be divided broadly into several categories ( Fig. 1 ): 1. Intronic lncRNAs are located within an intron of a coding gene; 2. intergenic lncRNAs (lincRNAs) are present between two protein-coding genes; 3. bidirectional lncRNAs are expressed within the vicinity (within 1 kb) of a coding transcript of the opposite strand; 4. enhancer lncRNAs (e-lncRNAs) are present in the enhancer regions close to the promoter; 5. sense: or 6. antisense lncRNAs are those that overlap with one or more introns and exons of a different transcript on the same or opposite strand, respectively (Devaux et al., 2015; Hirose et al., 2014; H. Takahashi & Carninci, 2014) . Non-coding repeats are another important class of lncRNAs that can have biological functions.
While a location-based classification may be useful for their recognition and annotation, an accurate classification of lncRNAs with respect to their biological role or biological activity is lacking.
Efforts to develop lncRNA databases have used systematic identification and annotation of lncRNAs within the human genome. The cDNA clone analysis within the FANTOM project led to the identification of over 23,000 lncRNAs (Carninci et al., 2005) , while the GENCODE-ENCODE project identified approximately 24,000 lncRNA producing loci (Derrien et al., 2012 ). An analysis of a compendium of 7256 RNAseq libraries from tumors, normal tissues, and cell lines and comprehensively delineated genome-wide lncRNA expression reported the identification of 58,648 lncRNA genes (Iyer et al., 2015) .
Mechanisms of action
As may be expected from their structural diversity, a wide range of functions have been described for lncRNAs. These include gene transcription, epigenomic regulation, translation of protein-coding genes, RNA turnover, chromatin organization, and genome defense (Ferraiuolo et al., 2010) . Notably, most of the functions described to date involve regulation of gene expression, both of protein-coding genes or other non-coding RNAs, through a multitude of mechanisms as outlined in Table 1 and Fig. 2 . LncRNAs differ from small RNAs in both complexity and length. The structural complexity of lncRNAs offers multiple possibilities for interactions with DNA, RNA, and/or proteins that depend on the secondary and tertiary structures. Likewise, the length of lncRNAs enables the formation of multi-component complexes such as those involved in epigenetic regulation of transcription. LncRNAs may be transcribed from DNA in several orientations and can interact with genomic DNA elements, as well as with proteins in multiple configurations.
While the majority of lncRNA are present within the cytoplasm, some lncRNAs are primarily confined within the nucleus (Z. Zhang et al., 2014) . Trans-acting nuclear lncRNAs can act in a tissue-specific manner in conjunction with chromatin modifiers such as histonemodifying complexes and DNA methyltransferases, to epigenetically regulate or to modulate transcription (Tao et al., 2013) . However, the mechanism by which these lncRNAs can recognize specific genomic loci is not well understood. It is hypothesized that interactions with genomic regions may be dictated by secondary or tertiary structural elements. Efforts to define and categorize RNA structural modules may enable systematic approaches to evaluate this hypothesis in the future. Some lncRNAs have been shown to maintain the nuclear architecture by scaffolding the assembly of DNA-RNA-protein interface at specific locations. In contrast, cis-acting lncRNAs may be able to regulate gene expression in a locus and allele-specific manner because of their genomic proximity to their targets. Cis-acting lncRNAs have been implicated in genomic imprinting, dosage compensation, and enhancer functions (Chen, Xu, & Liu, 2013; Xu et al., 2013) . In such cases, modulation of neighboring gene expression can occur via direct binding or through the recruitment of chromatin-binding proteins that can modify the chromatin structure in the vicinity. While most of the well-studied lncRNAs regulate cellular activities at the nuclear level, others are localized within the cytosol and mediate post-transcriptional control via RNA-RNA interactions (Chapman et al., 2014) . They can act as sponges and interact with short non-coding RNAs, such as miRNAs to simultaneously influence the expression of several thousands of miRNAtarget genes leading to an overall change in cellular physiology.
The functional heterogeneity of lncRNAs is further emphasized by their ability to contribute to multi-protein complex formation and participate in protein localization and function. In addition, a role for lncRNA as mediators of intercellular signaling is also being recognized by studies that have demonstrated the presence of lncRNA within extracellular vesicles, their release during conditions of cellular stress, and their ability to modulate cellular responses in recipient cells after uptake of these vesicles (Kogure, Yan, Lin, & Patel, 2013; K. Takahashi, I.K. Yan, H. Haga et al., 2014; K. Takahashi, I.K. Yan, K. Wood et al., 2014) .
LncRNA in human cancers
The ability of lncRNA to alter cellular physiology by altering gene expression raises the possibility that deregulated lncRNA expression may contribute to disease pathophysiology. Altered expression of lncRNA has been reported in many cancers and in other disease settings. Based on the emerging literature, lncRNA may be useful in elucidating Fig. 1 . Non-coding RNA. Non-coding RNA comprise a much larger portion of the human genome than protein-coding RNA, which comprise b3% of the genome. Non-coding RNAs are arbitrarily classified into short and long non-coding RNA based on transcript size. LncRNA can be designated as Intergenic, Intronic, Enhancer, Sense, Antisense, or Bidirectional based on their genomic location relative to that of nearby protein-coding genes.
disease pathogenesis and pathophysiology. In settings where alterations in lncRNA are associated with disease states, lncRNA may have roles as therapeutic targets or as biomarkers of disease (Table 2) . Recent studies implicate the potential role of lncRNAs in cancer development by virtue of their ability to interact with DNA, RNA, proteins, and/or their combinations, and their potential to modulate many of the hallmarks of cancer (Fig. 3) . A specific group characterized by non-coding repeats can activate immune responses and contribute to disease progression (Chiappinelli et al., 2015; Leonova et al., 2013; Rooney, Shukla, Wu, Getz, & Hacohen, 2015; Roulois et al., 2015; Tanne et al., 2015) . Examples include LINE-1. HERV, Satellites, and TERRA. In addition, the LINE-1 repeat (CoT-1) may affect chromatin formation. These repeats are actively reverse transcribed and re-incorporate in the genome in cancers, thus causing an expansion of specific genomic regions (Bersani et al., 2015; Hall et al., 2014; Iskow et al., 2010; E. Lee et al., 2012; Rodic et al., 2015) . TERRA plays a role in telomere extension through the alternative lengthening of telomeres (ALT) pathway (Flynn et al., 2011) .
The emergence of comprehensive detection technology such as RNA-seq has enabled the cataloging of databases with information on several lncRNAs that are deregulated or aberrantly expressed in several types of cancers such as hepatocellular carcinoma (HCC), gastric cancer, renal cancer, colorectal cancer, glioma, prostate cancer, and others. High-throughput, comprehensive and multi-dimensional data analyses have extended our knowledge about molecular regulatory mechanisms of lncRNAs that can control specific tumor-related behavior, thus adding a new stratum of key mediators and regulatory complexity during the evolution of cancer.
To highlight these, we will use liver cancers as an illustrative example. Liver cancers such as HCC are ideal to study lncRNA targets for treatment because liver uptake and delivery may be feasible for some therapeutic approaches. Several lncRNAs have been identified to play a functional role in HCC initiation and progression, as well as associated with recurrence, metastases, or prognosis. These RNA genes could regulate epigenetic events in conjunction with chromatin-modifying factors such as chromatin, histone-modifying enzymes, and DNA-methylating agents leading to altered expression of target genes. The downstream cellular functions of these lncRNA transcripts are better understood than the mechanisms by which the expressions of these lncRNAs are regulated, or their relevance to genetic or somatic mutations related . Braconi, N. Valeri, et al., 2011) to tumorigenesis. Examples of some functionally active lncRNAs that are associated with HCC are listed in Table 3 . We emphasize that these may represent just the tip of the iceberg, as many other lncRNA related to HCC or other cancers remain to be identified. To illustrate the diversity of functional mechanisms, we discuss a few of these herein (Fig. 4) . A classic example of lncRNA gene networking in HCC is Highly upregulated lncRNA in liver cancer (HULC). Overexpression of HULC is associated with low-stage and low-grade tumors, implying a functional role in early stage of cancer progression. The cAMP response elementbinding protein (CREB) binds to a binding site in the promoter region of HULC, and this association leads to an autoregulatory loop of HULC with miR-372 via its conserved target site causing inhibition of translational repression of the catalytic subunit of PKA (PRKACB), a miR-372 target. This in turn increases the phosphorylation of CREB, making it more available to bind to proximal promoter of HULC. Overall, this autoregulatory loop leads to increased expression of HULC in HCC (J. Wang et al., 2010) . HULC can also promote proliferation of HCC by targeting and suppressing p18. IGF2BP1, an oncofetal protein acts in trans to regulate HULC stability and expression by acting as a guide by bringing HULC into close proximity to the CCR4-NOT1 deadenylase complex . Metastasis associated in lung adenocarcinoma transcript 1 (MALAT-1) is another lncRNA that is upregulated in HCC; Although the mechanistic contribution of MALAT-1 to HCC is not known, MALAT-1 is associated with alternative splicing and interacts with SF2/ASF and CC3 antigen to modulate SR proteins (serine/arginine-rich family of nuclear phosphoproteins) that regulate splicing of various pre-mRNAs (Lai et al., 2012; R. Lin et al., 2007) . LncRNA high expression in HCC (HEIH) can contribute to cell cycle arrest by association with enhancer of zeste homolog 2, a part of polycomb repressive complex 2 that leads to its recruitment to p16 promoter region, thereby preventing the expression of p16 gene (J. J. Huang et al., 2015; F. Yang, L. Zhang et al., 2011) . Non-coding repeat LINE-1 insertions occur with high frequency in HCC (Shukla et al., 2013) LncRNAs can also bind with miRNAs as sponges to regulate gene expression. These examples serve to illustrate the diversity of many unique lncRNA-based mechanisms in HCC.
The detection of certain lncRNAs in body fluids, like urine and plasma, makes them potential biomarkers of disease, similar to circulating miRNA. To explore the potential role of lncRNA as biomarkers, it will be necessary to establish the expression and stability of circulating lncRNAs in healthy and diseased states. For example, plasma levels of lncRNA HULC are higher in patients with HCC patients than in healthy controls. Similarly, PCA3, a prostate-specific lncRNA that is significantly overexpressed in prostate cancer, may be a promising candidate for a diagnostic biomarker for prostate cancer (G. L. Lee et al., 2011) . Establishing the relationship between circulating lncRNA and the disease course may yield prognostic markers, as suggested by a report of ncRNA MALAT-1, as an early prognostic indicator of poor survival rate in HCC.
Although the correlation between lncRNAs and human cancers is recognized, detailed mechanistic information regarding the contribution of lncRNA to these cancers is currently lacking. Nevertheless, the rapidly growing interest and emerging data are likely to provide many new mechanistic insights into the contributions of lncRNA in cancer, and thereby are expected to identify novel candidates for therapeutic intervention or biomarkers.
Therapeutic approaches to targeting lncRNA in cancers
Differential expression of lncRNA in tumors compared with normal tissues has been reported for many different cancers. The identification of lncRNA that are involved in cellular processes contributing to oncogenesis, tumor suppression, or tumorigenesis provides opportunities to develop novel therapeutics for cancer that are based on targeting lncRNA (Kimura et al., 2015; Sasaki et al., 2009 ). These genes differ from protein-coding RNA or miRNA in several ways that need to be considered in analyzing their effects or in exploring their therapeutic potential. First, their structural complexity and participation in multicomponent complexes provides several potential targetable critical residues to modulate structure-based interactions. Second, they can subserve key regulatory roles in gene expression at absolute expression levels that are low in comparison with protein-coding genes. Third, they demonstrate tissue or cell-type specificity in expression. In addition, their effects can result from very diverse mechanisms of action, and they may also participate in intercellular communication. Finally, our current understanding of RNA gene function emphasizes the combinatorial nature of their action, which can result in complex interactions that incorporate multiple associated effectors. As a consequence, the functional impact of targeting lncRNA needs to be analyzed in a systemic context rather than as an individual target (See Table 4 .).
Several different types of approaches can be considered to target lncRNA and to modulate their expression for therapeutic purposes (Fig. 5) .
Silencing of lncRNAs
Similar to other genes, lncRNA can be targeted by using specific small interfering RNAs (siRNAs) that associate with RISC (RNA-induced silencing complex) complex and bind to specific target sequence based on complementarity leading to argonaute-mediated degradation of target sequence. For example, in a study by Hung et al., siRNA against promoter of CDKN1A antisense DNA damage activated RNA (PANDA) significantly reduced its expression and sensitized human fibroblasts to doxorubicin-induced apoptosis (Kimura et al., 2015; Regha, Latos, & Spahn, 2006; F. Wang, J.H. Yuan et al., 2014) .
Natural antisense transcripts
Natural antisense transcripts (NATs) are a type of lncRNA and their use illustrates an example of extending knowledge of lncRNA to design effective therapeutics. Inhibition of NATs can increase sense mRNA transcript levels (Modarresi et al., 2012) and the use of AntagoNATs is being evaluated as a therapeutic approach to upregulate the expression of specific sense mRNA (H. Takahashi & Carninci, 2014) .
Antisense oligonucleotide
Therapeutic strategies based on antisense oligonucleotide (ASO) could be used to target the expression and function of specific lncRNAs. ASOs are single-stranded oligonucleotides that offer specific complementarity and RNase H-mediated degradation of target sequence. The feasibility of ASO-mediated knockdown to modulate MALAT-1 function has been demonstrated in lung cancer cells and murine xenografts where metastasis was restricted. ASO may be more effective than siRNAs for lncRNA targets in which the secondary structure of the lncRNA might preclude or limit optimal association with a siRNA. However, as with other ASO-targeting strategies, the adequacy of cellular uptake and potential for off-target effects needs to be considered Kotake et al., 2011; Lebo, Niederer, & Zappulla, 2015; Zappulla & Cech, 2006) .
Locked nucleic acid GapmeRs
The use of these provides an alternative to RNAi-knockdown of upregulated lncRNAs. These single-stranded oligonucleotide consist of a DNA stretch flanked by locked nucleic acid (LNA) nucleotides and, similar to ASOs, form base pairs with target lncRNA to induce degradation via RNAse H-dependent mechanism (Yang, Lu, & Yuan, 2014) . Inhibition of MALAT-1 using GapmeRs resulted in a functional reduction in blood flow recovery and capillary density after hind limb ischemia (Michalik et al., 2014) . However, this approach is currently limited only to nuclear localized oncogenic lncRNAs.
Ribozymes or deoxyribozmes
Catalytic degradation is another therapeutic strategy. These enzymes can target RNA and cleave in a site-specific manner via a protein-independent mechanism. 'Hammerhead'-ribozymes are designed to have~20 nt long arms flanking a central loop and these Table 4 LncRNA-based therapeutic approach in cancer.
Agent
Description and mechanism Progress made Small interfering RNAs (siRNAs) Double-stranded RNAs that associate with RISC complex and exhibit argonaute-mediated degradation depending on perfect sequence complementarity Small-molecule drugs Chemical compounds that block the activity of target lncRNAs by structure-specific docking to regulate activity Preclinical studies "arms" facilitate the binding with its targets. A significant inhibition of liver metastasis was observed by anti-VEGFR-1/2 ribozymes in preclinical studies in colon cancer model (Pavco et al., 2000) . However, secondary structures of lncRNAs often disrupt efficient binding of these molecules to specific targets.
Aptamers
The use of single-stranded oligonucleotide or peptide aptamers could overcome limitations imposed by structural features as they could bind by forming tertiary structures with their targets. Thus, they may provide a greater specificity than siRNAs, ASOs, or ribozymes. Moreover, the chemical structure of aptamers could be modified to enhance their stability and half-life. Aptamer-based therapeutics are promising and undergoing clinical trials for many different indications such as non-small-cell lung cancer, renal cell carcinoma, and acute myeloid leukemia (Vitiello, Tuccoli, & Poliseno, 2015) . In 2004, an anti-VEGF aptamer (Eyetech Pharmaceutics/Pfizer) was approved by FDA for macular degeneration.
Small-molecule inhibitors
As discussed above, lncRNAs exhibit dynamic binding affinities to various cellular components. Small molecules can mask the binding site for lncRNAs and prevent the association with its binding partners or antagonistic oligonucleotide sequences to disrupt interactions that are linked to altered function in disease-related lncRNA. For example, a small-molecule inhibitor that prevents the binding of an oncogenic lncRNA, HOTAIR with its binding partners could restrict tumor cell invasion, angiogenesis, and metastatic potential (Tsai, Spitale, & Chang, 2011) . Small molecules and oligonucleotides can also be used to interfere with the formation of RNA structures and disrupt folding patterns that modulate function.
RNA destabilizing elements
These can regulate lncRNA expression at the genomic level, and confer a knockout-like effect on gene function. RNA destabilizing elements (RDEs) have been successfully employed to reduce MALAT-1 expression (Miller et al., 2007) .
Synthetic lncRNA mimics and other constructs
The use of synthetic mimics are being developed and tested for their ability to act as a decoy to block transcription of target genes or to restore their function. Alternatively, a plasmid BC-819 (DTA-H19) has been designed to specifically mediate its action through high abundance lncRNA H19 promoter to induce high levels of diphtheria toxin in tumors. The use of this construct has been shown to lead to an overall reduction in tumor size in human trials in several carcinomas although the underlying mechanisms need to be investigated (Mizrahi et al., 2009) .
Several approaches to target lncRNA for therapeutic purposes can be considered once critical disease-relevant contributions of these genes have been identified. A major challenge of all of these approaches is to accomplish target-specific delivery. The use of synthetic nanoparticles for delivery of biologically active constructs has been extensively investigated. An alternative approach involves the use of extracellular vesicles, biologically derived particles that are involved in intercellular communication, and could be packaged with RNA genes for successful targeted therapy (Hongay et al., 2006; Kimura et al., 2015) . We have recently shown that lncRNAs within extracellular vesicles retain functional activity after they are taken up by recipient cells (K. Takahashi, I.K. Yan, T. Kogure et al., 2014) . The use of extracellular vesicles as delivery vehicles for lncRNA is thus highly attractive. Effective, target-specific therapy can be designed by fusing exosome membrane protein with specific peptides. Other potential advantages may include immune tolerance with the use of autologous vesicles, ability to traverse the blood-brain barrier, and more effective tissue penetration into target tissues such as tumors.
Therapeutic resistance is a major challenge that limits the efficacy of cancer treatments. The role of lncRNAs in conferring differential drugresistance phenotype is becoming appreciated, and several mechanisms for therapeutic resistance are now recognized. These include involvement of lncRNA in modulating survival signaling pathways, drug transporter expression and elimination, sensitization to apoptosis, DNA repair and cell cycle progression, and intercellular communication mediated by extracellular vesicles (Fig. 6) . A proposed mechanism involves trans-regulatory modulation of P-glycoprotein (P-gp) that regulates drug elimination in resistant cells. P-gp is in turn regulated by multidrug resistance-related and upregulated lncRNA (MRUL) with inhibition of MRUL leading to increased chemotherapeutic drug-mediated apoptosis via reduction of P-gp expression and followed by impaired chemotherapeutic expulsion (Thiebaut et al., 1987; Y. Wang, D. Zhang et al., 2014) . Some lncRNAs have the ability to re-sensitize chemoresistant cancer cells to therapeutic agents like cisplatin by modulating DNA damage response pathways. Cisplatin-mediated upregulation of HOTAIR in human lung adenocarcinoma cells suppressed p21 (WAF1/CIP1) signaling pathway and caused a G 0 /G 1 arrest by modulating the p53 expression (Z. Liu et al., 2013) . Another lncRNA, urothelial cancerassociated 1 (UCA1) increased cisplatin-mediated resistance in human bladder cancer cells by regulating the Wnt signaling pathway. A proposed mechanism is upregulation of wingless-type MMTV integration site family member 6 (Wnt6), making this a potential target to overcome chemoresistance (Fan et al., 2014) . Similarly, lncRNA AK126698 modulated cisplatin resistance in non-small-cell lung cancer cells via Wnt pathway (Hou et al., 2014; Y. Yang, H. Li et al., 2013) . We identified a novel lncRNA, lincRNA-ROR to be involved in mediating chemoresistance in human hepatocellular cells. Interestingly, this lncRNA was highly enriched within extracellular vesicles derived from HCC tumor cells and caused an increased lincRNA-ROR expression and reduced chemotherapy-induced cell death in recipient cells by modulating levels of TGFβ (tumor growth factor-beta) (K. Takahashi, I.K. Yan, T. Kogure et al., 2014) . LncRNA GAS5 renders glucocorticoid resistance by assuming a secondary structure that competes with the sequence within the response gene promoter region (Kino et al., 2010) . PANDA contributes to anthracycline resistance in a subset of breast cancer cells by coordinating with NF-YA, a nuclear transcription factor that regulates apoptosis. Down-regulation of PANDA led to increased chemotherapy sensitivity thus, suggesting a crucial role in drug resistance (Malek, Jagannathan, & Driscoll, 2014) .
Although in vitro studies may provide promising results with regards to lncRNA function and their use as therapeutic targets, in vivo validation is extremely challenging and requires optimization at various levels. The poor conservation of lncRNA across species can confound the interpretation of data from animal studies. Our understanding of the mechanisms of action is rudimentary, and many intriguing questions remain unanswered such as the recruitment criteria for chromatin-remodeling complexes, whether or not the binding partners of lncRNAs are constant, or the impact of environment, localization, or associated disease states on lncRNA expression and function. The advent of genome engineering capabilities such as TALEN or CRISPR/Cas9 methodologies will enable the detailed study of lncRNA function (Hainer, Charsar, Cohen, & Martens, 2012; Hongay et al., 2006) . Definition of the repertoire of lncRNA in normal tissues or cells and in disease conditions will be necessary. There is a need to develop adequately sensitive detection techniques, and to comprehensively define structural and functional motifs and modules. Even with established targets for intervention, careful in vivo analyses will be necessary, followed by validation in appropriate patient cohorts. As the pace of research in lncRNAs progresses, addressing these challenges and gaps will provide opportunities for the development of novel therapeutic strategies based on targeting lncRNA for human cancers and other diseases.
Conclusions
Our current knowledge regarding lncRNA provides the basis and justification to further develop applications of lncRNA as disease markers and therapeutic targets. As discussed above, lncRNAs can interact with DNA, mRNA, ncRNAs and proteins to alter cellular physiology, can be deregulated in diseases such as cancer, and can form the basis for therapeutic intervention. Although a holistic and integrated approach that incorporates lncRNA with other proteins and genes will be necessary to successfully develop effective therapies, adding these RNA genes to our future armamentarium of therapeutics is likely to be very beneficial by providing new opportunities for intervention.
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